Literature DB >> 18097040

Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells.

Ralf-Holger Voss1, Ralph A Willemsen, Jürgen Kuball, Margarete Grabowski, Renate Engel, Ratna S Intan, Philippe Guillaume, Pedro Romero, Christoph Huber, Matthias Theobald.   

Abstract

A promising approach to adoptive transfer therapy of tumors is to reprogram autologous T lymphocytes by TCR gene transfer of defined Ag specificity. An obstacle, however, is the undesired pairing of introduced TCRalpha- and TCRbeta-chains with the endogenous TCR chains. These events vary depending on the individual endogenous TCR and they not only may reduce the levels of cell surface-introduced TCR but also may generate hybrid TCR with unknown Ag specificities. We show that such hybrid heterodimers can be generated even by the pairing of human and mouse TCRalpha- and TCRbeta-chains. To overcome this hurdle, we have identified a pair of amino acid residues in the crystal structure of a TCR that lie at the interface of associated TCR Calpha and Cbeta domains and are related to each other by both a complementary steric interaction analogous to a "knob-into-hole" configuration and the electrostatic environment. We mutated the two residues so as to invert the sense of this interaction analogous to a charged "hole-into-knob" configuration. We show that this inversion in the CalphaCbeta interface promotes selective assembly of the introduced TCR while preserving its specificity and avidity for Ag ligand. Noteworthily, this TCR modification was equally efficient on both a Mu and a Hu TCR. Our data suggest that this approach is generally applicable to TCR independently of their Ag specificity and affinity, subset distribution, and species of origin. Thus, this strategy may optimize TCR gene transfer to efficiently and safely reprogram random T cells into tumor-reactive T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097040     DOI: 10.4049/jimmunol.180.1.391

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

Review 1.  New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Authors:  Thomas M Schmitt; Ingunn M Stromnes; Aude G Chapuis; Philip D Greenberg
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

Review 2.  Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.

Authors:  X Wang; I Rivière
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

3.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Authors:  D H Aggen; A S Chervin; T M Schmitt; B Engels; J D Stone; S A Richman; K H Piepenbrink; B M Baker; P D Greenberg; H Schreiber; D M Kranz
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

4.  T-cell receptor gene transfer for the treatment of leukemia and other tumors.

Authors:  Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

Review 5.  Treating cancer with genetically engineered T cells.

Authors:  Tristen S Park; Steven A Rosenberg; Richard A Morgan
Journal:  Trends Biotechnol       Date:  2011-06-12       Impact factor: 19.536

Review 6.  New cell sources for T cell engineering and adoptive immunotherapy.

Authors:  Maria Themeli; Isabelle Rivière; Michel Sadelain
Journal:  Cell Stem Cell       Date:  2015-04-02       Impact factor: 24.633

7.  Advanced malignant melanoma: immunologic and multimodal therapeutic strategies.

Authors:  Niels Halama; Inka Zoernig; Dirk Jaeger
Journal:  J Oncol       Date:  2010-03-09       Impact factor: 4.375

Review 8.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

9.  Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.

Authors:  Longhao Sun; Hao Guo; Ruoyu Jiang; Li Lu; Tong Liu; Xianghui He
Journal:  Tumour Biol       Date:  2015-08-07

Review 10.  T cell receptor gene therapy for cancer.

Authors:  Thomas M Schmitt; Gunnar B Ragnarsson; Philip D Greenberg
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.